title: Targeting IKKβ for the treatment of rheumatoid arthritis.
authors.affiliation: GlaxoSmithKline R&D, Medicines Research Centre, Stevenage, Hertfordshire, UK. paul.a.bamborough@gsk.com
authors.forename: Paul
authors.initials: P
authors.lastname: Bamborough
authors.forename: Mary A
authors.initials: MA
authors.lastname: Morse
authors.forename: Keith P
authors.initials: KP
authors.lastname: Ray
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000235:genetics / Q000503:physiopathology; D016503:Drug Delivery Systems; D015195:Drug Design; D006801:Humans; D051550:I-kappa B Kinase / Q000037:antagonists & inhibitors* / Q000378:metabolism; D016328:NF-kappa B / Q000037:antagonists & inhibitors / Q000378:metabolism; D047428:Protein Kinase Inhibitors / Q000494:pharmacology
chemical_list: D000893:Anti-Inflammatory Agents; D016328:NF-kappa B; D047428:Protein Kinase Inhibitors; D051550:I-kappa B Kinase